Cannara Biotech Inc. has announced its fiscal third quarter 2024 financial and operating results for the three and nine-month periods ended May 31, 2024. Gross cannabis revenues before excise taxes increased to $26.2 million in Q3 2024 from $20.6 million in Q3 2023, a $5.6 million or 27.6%, increase. Total revenues, net of excise taxes, increased to $19.5 million in Q3 2024 from $15.9 million in Q3 2023, a $3.6 million or 22.6% increase. The company delivered a thirteenth consecutive quarter of positive Adjusted EBITDA 1 of $2.8 million.

Cannara Biotech Inc., a client of our Bristol Investor Relations firm, is a vertically integrated producer of premium-grade cannabis and derivative product offerings at affordable prices with two mega facilities based in Quebec.

Read the full press release here: Cannara Biotech Reports Q3 2024 Financial Results